Impact of fremanezumab on response rates, acute medication use, and disability in patients with episodic migraine who have failed at least one prior migraine preventive medication

被引：0
作者：
Winner, Paul K. [1 ]
Singh, Rashmi B. Halker [2 ]
Cohen, Joshua M. [3 ]
Yang, Ronghua [3 ]
Yeung, Paul P. [3 ]
Ramirez Campos, Verena [4 ]
机构：
[1] Premiere Res Inst, W Palm Beach, FL USA
[2] Mayo Clin, Phoenix, AZ USA
[3] Teva Pharmaceut, Frazer, PA USA
[4] Teva Pharmaceut, Buenos Aires, DF, Argentina
来源：
JOURNAL OF HEADACHE AND PAIN | 2018年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O38
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy Of Fremanezumab in Patients With Chronic Migraine With or Without Concomitant Use of Preventive Medication
    Goadsby, Peter J.
    Dodick, David W.
    Silberstein, Stephen D.
    Yeung, Paul P.
    Blankenbiller, Tricia
    Ning, Xiaoping
    Yang, Ronghua
    Ma, Yuju
    Aycardi, Ernesto
    Bigal, Marcelo E.
    [J]. NEUROLOGY, 2018, 90
  • [32] Efficacy of fremanezumab in patients with chronic migraine with or without concomitant use of preventive medication
    Goadsby, Peter J.
    Dodick, David W.
    Silberstein, Stephen D.
    Yeung, Paul P.
    Blankenbiller, Tricia
    Ning, Xiaoping
    Yang, Ronghua
    Ma, Yuju
    Aycardi, Ernesto
    Bigal, Marcelo E.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [33] INDIRECT COMPARISON OF THE EFFICACY OF FREMANEZUMAB VERSUS ERENUMAB IN EPISODIC MIGRAINE PATIENTS WHO HAD FAILED 2-4 PRIOR MIGRAINE PREVENTIVE TREATMENTS
    Patterson-Lomba, O.
    Thompson, S.
    Gandhi, S. K.
    Yang, R.
    Cohen, J.
    Mu, F.
    Young, J.
    [J]. VALUE IN HEALTH, 2019, 22 : S737 - S737
  • [34] Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response
    Buse, Dawn C.
    Krasenbaum, Lynda J.
    Seminerio, Michael J.
    Packnett, Elizabeth R.
    Carr, Karen
    Ortega, Mario
    Driessen, Maurice T.
    [J]. PAIN AND THERAPY, 2024, 13 (03) : 511 - 532
  • [35] Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients With Chronic Migraine: Results of a 1-Year Study
    McAllister, Peter
    Yeung, Paul P.
    Cohen, Joshua
    Gandhi, Sanjay
    Yang, Ronghua
    [J]. NEUROLOGY, 2019, 92 (15)
  • [36] Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Chronic Migraine: Results of a 1-Year Study
    McAllister, P.
    Cohen, J. M.
    Gandhi, S. K.
    Yang, R.
    [J]. HEADACHE, 2019, 59 : 114 - 114
  • [37] Efficacy of Fremanezumab in Patients With Episodic Migraine Who Had Prior Use of Topiramate or OnabotulinumtoxinA
    Kudrow, David
    Sakai, Fumihiko
    Yeung, Paul P.
    Blankenbiller, Tricia
    Ning, Xiaoping
    Yang, Ronghua
    Ma, Yuju
    Aycardi, Ernesto
    Bigal, Marcelo E.
    [J]. NEUROLOGY, 2018, 90
  • [38] Pooled analysis of efficacy of fremanezumab for reducing disability and acute medication overuse in migraine patients
    Ashina, S.
    Cohen, J.
    Ning, X.
    Ramirez-Campos, V.
    Seminerio, M.
    Janka, L.
    Silberstein, S.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 156 - 156
  • [39] Efficacy of Fremanezumab in Patients with Episodic Migraine Who Had Prior Use of Topiramate or OnabotulinumtoxinA
    Kudrow, D.
    Sakai, F.
    Yeung, P. P.
    Blankenbiller, T.
    Ning, X.
    Yang, R.
    Ma, Y.
    Aycardi, E.
    Bigal, M.
    [J]. HEADACHE, 2018, 58 : 169 - 170
  • [40] Reversion from medication overuse with fremanezumab treatment in patients with inadequate response to multiple migraine preventive medication classes
    Ashina, Sait
    Campos, Verena Ramirez
    Cohen, Joshua
    Janka, Lindsay
    Krasenbaum, Lynda J.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 213 - 214
12345